cyrilzakka/clinical-trials huggingface dataset:
MRD-directed Therapy for Low-risk and Intermediate-risk AML.

Acute myeloid leukemia(AML) patients with favorable and intermediate cytogenetics at diagnosis are generally excluded from first-line allo-SCT. However, these patients may eventually relapse in some cases. Our previous study found that stratification of treatment based on cytogenetics and therapeutic response could benefit low and intermediate AML. To further verify the results, we conducted a prospective multi-center study. The purpose of this study is to establish risk stratification based on cytogenetics and minimal-residual-disease (MRD) analysis to determine whether a MRD-directed therapy for low and intermediate AML patients has positive results in terms of overall survival.


Eligibility Criteria:
Inclusion Criteria:

Low-risk and intermediate-risk AML Subjects (or their legally acceptable representatives) must have signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study.

Exclusion Criteria:

Any abnormality in a vital sign (e.g., heart rate, respiratory rate, or blood pressure) Patients with any conditions not suitable for the trial (investigators' decision)
Use of Contrast Enhanced Spectral Mammography (CESM) for Women With Palpable Breast Abnormalities

Contrast Enhanced Spectral Mammography (CESM) is an advanced form of mammography which is performed after injection of contrast or dye into a vein in the arm. This dye is the same dye that is used for CT scans. This type of mammogram includes a regular mammogram as well as additional pictures with the dye.

This particular study is being done to determine if by adding the dye in the veins the investigators are better able to identify the cause of the lump than if they just did the regular mammogram alone.


Eligibility Criteria:
Inclusion Criteria:

* Women presenting for mammographic evaluation of an undiagnosed palpable mass found either by self examination and/or examination by referring physician

Exclusion Criteria:

* Age \< 25 years old
* Male patients
* Pregnant or lactating patients
* Patients with allergy to iodinated contrast
* Patients with a history of renal disease or patients over 70 with a creatinine \> 1.3. Creatinine must have been done within the last 12 weeks.
Swan-Ganz CCOmbo V for Obtaining an Optimal Depth of Right Internal Jugular Venous Catheter

The investigators will perform a study to create formula for the optimal insertion depth of right internal jugular vein catheter.

Patients scheduled for cardiac surgery were studied.Determine the optimal insertion depth of right internal jugular vein catheter using Swan-Ganz Continuous Cardiac Output Thermodilutioon Cather (Swan-Ganz CCOmbo V).The investigators measure the distance between the insertion point and the junction between right atrium and superior vena cava using Swan-Ganz CCOmbo V.

Eligibility Criteria:
Inclusion Criteria:

* Adult patient over 18 years of age undergoing mitral valve or/and tricuspid valve
* Surgery under general anesthesia, requiring Swan-Ganz Continuous Cardiac Output Thermodilutioon Cather (Swan-Ganz CCOmbo V) insertion through the right internal jugular vein.

Exclusion Criteria:

* A change in the mediastinal structure from previous neck surgery,thoracic surgery or cardiac surgery
* Extracardiac vascular anomaly
* Anatomical abnormality in neck and thorax
* Refusal to enrol
Brain Oxygenation Marker for Cognitive Function in Healthy Adults

This study aims to identify a cortical oxygenation marker for cognitive function using functional Near Infrared Spectroscopy in healthy adults.

This study will aim to establish a model between the cortical oxygenation and cognitive performances given modulations by experimental conditions including the cognitive workload and the time-on-task, and individual variabilities such as the age or the gender.

Eligibility Criteria:
Inclusion Criteria:

1. Males and Females 25-45 years old
2. BMI between 18.5 kg/m2 and 29.9 kg/m2
3. Conditions for study procedure compliance:

   * Willing and able to sign an informed consent form
   * Be fluent in English (self-reported C1 or C2 English level)
   * Be able to provide a cortical oxygenation signal (based on feasibility to fix the measurement device on the scalp, which can be altered by hair thickness)
   * Be dominant right-handed
   * Have a normal or corrected-to-normal vision
   * Be expected to comply with the protocol

Exclusion Criteria:

The project exclusion criteria are:

1. Conditions that may affect cortical oxygenation:

   * Be insomniac (insomnia severity index, ISI, higher than 15 based on rating at the medical screening) or night shift worker (based on anamnesis)
   * Be currently diagnosed with migraine (based on anamnesis)
   * Be currently diagnosed with hypo- or hyper-tension (based on evaluation of BP measure against medical norms at the medical screening)
   * Have an historical or current neural, cerebrovascular, cardiovascular, or respiratory disease (based on anamnesis)
   * Have a heavy usual consumption of caffeine-based beverages i.e., more than 5 servings of caffeinated coffee/colas or tea or 1 serving of caffeinated energy drinks per day
   * Be a regular smoker (regularly defined as greater than 2 cigarettes per week)
   * Participate in a vigorous physical activity requiring more than 6 metabolic equivalents e.g., hiking, jogging at 10 km/h or more, carrying of heavy loads, bicycling fast at 23 km/h or more, basketball, soccer, and tennis single, greater than 4 times 45 minutes per week
2. Conditions that may affect cognition or the mental fatigue

   * Take illicit drugs (for e.g., cannabis, heroin, and cocaine)
   * Have an average alcohol consumption greater than 2 standard drinks per day over a week for males, and greater than 1 standard drink per day over a week for females.

   One standard drink contains 10-12 g of ethanol. Examples of standard drinks are one beer can (300 ml), one glass of wine (100 ml) or one glass of schnaps (30 ml).
   * Have a psychiatric disorder or be currently diagnosed with anxiety or depression
   * Be pregnant (verified by a pregnancy test in urine dipstick format) or seeking to become pregnant or breast feeding
3. Have a hierarchal or family relationship with any of the research team members.
4. Currently participating in another interventional study.
Structural Characteristics of Trunk and Limb Muscles in Cachectic Colorectal Cancer Patients

Until now, cancer is still associated with high morbidity and mortality, and is therefore a big issue for the public health. Colorectal cancer is the second leading cause of cancer death in developed countries. In advanced colorectal cancer, 60% of these patients develop cachexia. The presence of cachexia plays an important role in the high mortality rate of cancer. Cachexia is characterized by involuntary weight loss with loss of skeletal muscle with or without loss of fat mass.

The aim of this study is to determine the feasibility of taking muscle biopsies of cachectic colorectal cancer patients. Skeletal muscle characteristics will be compared between biopsies of the m. erector spinae and the m. vastus lateralis from cachectic colorectal cancer patients, non-cachectic colorectal cancer patients and healthy controls.

10 cachectic, 25 non-cachectic, and 25 healthy controls will be recruited for this study. It is an observational study, so measurements will be taken at one time point. Interventions/measurements:

* muscle biopsies
* blood samples
* 3D freehand ultrasound
* Short physical performance battery test
* handgrip strength
* questionnaires (activity pattern, quality of life)


Eligibility Criteria:
Cachectic colorectal cancer patients.

Inclusion criteria:

* minimum age of 18 years old
* unwanted weight loss \> 5% in the last 6 months OR \> 2% unwanted weight loss in combination with a BMI \< 20kg/m2 OR \>2% unwanted weight loss in combination with sarcopenia
* Cachexia staging score (CSS): 5-12

Exclusion Criteria:

* Mental of psychological condition
* Insufficient knowledge of the Dutch language
* Muscle diseases affecting the spine and lower limbs
* Bedridden

Non-Cachectic cancer patients.

Inclusion criteria:

* minimum age of 18 years old
* No unwanted weight loss \> 5% in the last 6 months OR \> 2% unwanted weight loss in combination with a BMI \< 20kg/m2 OR \>2% unwanted weight loss in combination with sarcopenia
* Cachexia staging score (CSS): 0-2

Exclusion criteria:

* Mental of psychological condition
* Insufficient knowledge of the Dutch language
* Muscle diseases affecting the spine and lower limbs
* Bedridden

Healthy controls.

Inclusion criteria:

- minimum age of 18 years old

Exclusion criteria:

* Mental of psychological condition
* Insufficient knowledge of the Dutch language
* Muscle diseases affecting the spine and lower limbs
* Bedridden
Frequency and Severity of Pleural Effusion Associated With the Use of Dasatinib in Patients With Chronic Myeloid Leukemia. A Descriptive, Mexican Multicenter Study

This is a retrospective, multicenter, descriptive analysis of patients with a diagnosis of chronic myeloid leukemia, treated with dasatinib for at least 45 days. The study will include 100 patients treated in different public centers in the Mexican Republic.


Eligibility Criteria:
Inclusion Criteria:

* Men and women ≥15 years of age
* Diagnosis of chronic myeloid leukemia in any phase that used dasatinib at any time between January 2008 and November 2014
* Have received dasatinib as part of their first-line or second-line treatment for at least 45 days

Exclusion Criteria:

* Patients who received dasatinib as part of any clinical trial
* Patients who do not have complete data on the data collection sheet
* Patients who do not have medical records available at the moment of the data verification
Trans-nasal Complete Nasolabial Cyst Excision

Background: Nasolabial cysts are rare benign epithelial nonodontogenic soft tissue cysts arising in the nasal alar region. Sublabial excision or transnasal endoscopic marsupialization is the standard treatment.

Patients and methods: Between 2019 and 2022, a descriptive retrospective study, including 20 patients who presented with Nasolabial cysts, was conducted.

A retrospective study of patients who were presented in the period from 2019 to 2022, with nasolabial cysts. Patients' files were checked for demographic data, clinical presentation, preoperative radiological investigations, histopathology, surgical approach, complications, and outcome.

Technique:

The surgery is carried out mainly using x5 magnification loupe and 0° degree sinoscope. Submucosal infiltration (lidocaine 2% and 1:100,000 adrenaline). An incision was made at the mucosal covering of the cyst wall and nasal floor in a transverse and anteroposterior direction. The mucosal flap is elevated and separated from the cyst wall and reflected toward the septum side. During dissection, cyst content is usually drained. The whole cyst wall was carefully dissected with sharp and blunt dissection from the mucous membrane, and laterally from the premaxillary area. Finally, endoscopic examination to check the operative bed and refashioning mucosal flap coverage. If mucosal flap is lacerated, then excised and operative bed left for healing by creeping from surrounding edges. Endoscopic trans-nasal complete excision has a shorter operative time, minimal intraoperative bleeding, and no postoperative pain or edema reported.

Eligibility Criteria:
Inclusion Criteria:

•Nasolabial cyst

Exclusion Criteria:

* Recurrent cases
* Previous operated
Stereotactic Body Radiotherapy for the Treatment of Solitary Bone Plasmacytoma

This project aims to propose a new approach in the treatment of solitary plasmacytoma: hypofractionated irradiation alone with stereotactic technique that may contribute to the successful treatment of this disease.

This work aims to apply this new technique with the primary objective of reducing the progression-free survival for multiple myeloma of patients treated for solitary plasmacytoma, as well as quantify overall survival, local control, toxicities and quality of life in a phase I trial / II.

Solitary plasmacytoma is a rare disease whose treatment has not evolved much in the last decades. The role of radiotherapy in the curative treatment of this entity was defined in a major publication in the 1980s and has since been proven to be the best practice in several other comparative trials, mostly retrospective. The radiotherapy dose of curative intent has also been described over the same period and remains unchanged to this day. Thus, local control, disease cure rate, and rate and progression time for multiple myeloma have been unaffected for almost 30 years.

Radiobiology of plasmacytoma cells is also not widely studied. The alpha / beta ratio, which defines the pattern of response of this disease to radiotherapy fractions and its response time, is also not well described. However, it is believed to be smaller in comparison to other hematological malignancies due to reports of cases of intrinsic radioresistance and late recurrence and reports of success with hypofractionated dose in isolated cases where stereotactic techniques were used such as base of skull and spine.

Eligibility Criteria:
Inclusion Criteria:

* Biopsy proven plasmacytic for the index lesion;
* Age between 18 and 85 years;
* ECOG scale performance of 0 to 2

Exclusion Criteria:

* Refuse to sign or inability to understand the term of free and informed commitment (TCLE);
* Technical limitations for treatment with SBRT among which is cited, but not limited to, weight greater than 115 Kg, inability to abduct limb to be treated in appendicular bone plasmocytomas, intolerable pain to remain in treatment position;
* Criteria for multiple myeloma at diagnosis: more than 10% of plasma cells in bone marrow biopsy, hypercalcemia greater than 11.5 mg/dL, serum creatinine greater than 2mg/dL, creatinine clearance less than 40mL/min , Hemoglobin less than 10g/dL.
* Previous cancer diagnosis and treatments;
* Previous bone events such as fractures and osteomyelitis in the bone in which the index lesion is found;
* Prior autoimmune diseases, even if controlled;
* Extra-medullary plasmacytoma requiring elective treatment of lymph node drainage;
* Current pregnancy
A 10-Week Efficacy and Safety Study of Gabitril in the Treatment of Adults With Generalized Anxiety Disorder

The purpose of this study is to evaluate the safety and efficacy of an investigational anti-anxiety medication relative to placebo in patients with generalized anxiety disorder (GAD).


Eligibility Criteria:
Inclusion Criteria:

* Subjects 18 to 64 years of age (inclusive) will be eligible to participate if they satisfy the DSM-IV-TR criteria for GAD, as well as meeting the required screening and baseline visit scores for a series of psychiatric evaluations (i.e., HAM-A, HADS, MADRS and CGI-S).

Exclusion Criteria:

* Have been previously unresponsive to two or more adequate courses of pharmacological treatment for GAD
* Have been diagnosed with any other psychiatric Axis I disorder (except GAD) as a principal diagnosis within the past six months
* Have been diagnosed with any eating disorder within the past six months
* Have any history of OCD, psychotic disorder, bipolar disorder or antisocial personality disorder
* Have any history of alcohol or substance abuse within 3 months of screening
* Have any history of seizures, including febrile seizures
* Have any history of head trauma associated with loss of consciousness within the past 15 years
Lingual Tonsil Hypertrophy Grading and Its Relation to Sociodemographic Factors and Clinical Symptoms

The aim of this research was to evaluate the lingual tonsil hypertrophy (LTH) grading of patients with dysphagia using videolaryngoscopy and determine the relation of LTH grades to sociodemographic factors and clinical symptoms.

Two groups of people were interviewed during this research - the LTH group and the control group - a total of 100 subjects. The first group was comprised of 50 individuals, who visited the otorhinolaryngologist at Lithuanian University of Health Sciences hospital, regarding dysphagia, and were diagnosed with LTH during endoscopy. The second group consisted of 50 healthy individuals without dysphagia, who did not have enlarged lingual tonsils during assessment using videolaryngoscopy. All subjects filled out the questionnaires, composed of RSI (Reflux Symptom Index) and DSQ (Dysphagia Screening Questionnaire) questionnaires, validated and verified for use in Lithuania, together with a questionnaire created specifically for this research for gathering sociodemographic data.

The LTH grade of all subjects was determined using DelGaudio and Friedman grading systems.

Eligibility Criteria:
Inclusion Criteria:

* Adults
* Consent for participating in the research
* No cognitive disorders or mental illnesses
* Complaining about difficulty swallowing (research group)
* Enlarged lingual tonsils on videolaryngoscopy (research group)
* Generally healthy, no complaints of swallowing disorders (control group)
* Normal-sized lingual tonsils (control group)

Exclusion Criteria:

* Refusal to participate in the research
* Younger than 18 and older than 80 years old
* Serious mental or cognitive conditions
Omega-3 Polyunsaturated Fatty Acids in Youth With ADHD

N-3 polyunsaturated fatty acids(N-3 PUFAs) is important in balancing the immune function and crucial for the developing brain. Deficiency in n-3 PUFAs might be linked to the poor cognitive performances resulting in inattention and hyperactivity in youth with attention deficit hyperactivity disorder (ADHD). N-3 PUFAs appears to be a promising treatment that is safe, beneficial to youth with ADHD. In this proposal, investigators aim the test the hypothesis that n-3 polyunsaturated fatty acids will be more effective than placebo in improving cognitive function in youth with ADHD after 12 weeks of intervention.

This is a 1-year study and a randomized, double-blind, and placebo controlled Clinical the study. investigators plan to enrol 100 subjects from Child and Adolescent Psychiatry Outpatient Clinic of China Medical University Hospital.Participants will be randomized into omega-3 polyunsaturated fatty acids or placebo group.The intervention period is 12 weeks. Evaluation of the cognitive function ( using Continuous Performance Test 3rd Edition ) of the subjects who are enrolled into the study will take place at baseline and after the 12th week. The symptom severity of ADHD will be measured with Swanson, Nolan, Pelham Questionnaire (SNAP-IV) at baseline, 2,4,8, and 12 weeks. The plasma level of n-3 polyunsaturated fatty acids, blood and salivary inflammatory markers will also be measured at the beginning and at the end of the study.

Eligibility Criteria:
Inclusion Criteria:

* DSM-5 diagnosed ADHD
* Age 6-18 years old at time of enrolment
* Conner's rating scares (CPRS) with scores \>= 2 standard deviations
* drug native or no medication use for past 6 months
* Signed informed consent

Exclusion Criteria:

* Intelligence quotient \<70
* Comorbid other psychiatric disorders, such as autism spectrum disorders, anxiety disorders, conduct disorders, schizophrenia, major depressive disorders and bipolar spectrum disorders
* Comorbid physical disorders, such as thyroid dysfunction, cerebral palsy
* Current using omega-3 supplements
* Allergy to omega-3
p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246

The purpose of this study is to make a preliminary assessment of the efficacy of a combined APR-246 and PLD chemotherapy regimen in patients with platinum-resistant recurrent high grade serous ovarian cancer (HGSOC) with mutated TP53. In addition, the study aims to assess the safety profile of the combined APR-246 and PLD chemotherapy regimen, to evaluate potential biomarkers, and to assess the biological activity in tumor and surrogate tissues. The trial will enroll at least 25 evaluable patients.


Eligibility Criteria:
Inclusion Criteria:

* Confirmed High Grade Serous Ovarian Cancer, and positive nuclear immunohistochemical (IHC) staining for p53
* Disease Progression between 4 weeks - 6 months after the last platinum-based treatment was administered
* At least a single measurable lesion
* Adequate organ function prior to registration
* Toxicities from previous cancer therapies (excluding alopecia) must have recovered to grade 1 (defined by National Cancer Institute \[NCI\] Common Terminology Criteria for Adverse Events \[CTCAE\] version 4.0). Chronic stable grade 2 peripheral neuropathy secondary to neurotoxicity from prior therapies may be considered on a case by case basis
* ECOG performance status of 0 to 2

Exclusion Criteria:

* Prior exposure to cumulative doses of doxorubicin \>400 mg/m2 or epirubicin \>720 mg/m2
* Hypersensitivity to PLD or to any of the excipients
* Unable to undergo imaging by either CT scan or MRI
* Evidence of any other medical conditions (such as psychiatric illness, infectious diseases, neurological conditions, physical examination or laboratory findings) that may interfere with the planned treatment, affect patient compliance or place the patient at high risk from treatment related complications
* Concurrent malignancy requiring therapy (excluding non-invasive carcinoma or carcinoma in situ)
* Is taking concurrent (or within 4 weeks prior to registration) chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy that is considered to be investigational (i.e., used for non-approved indications(s) and in the context of a research investigation). Supportive care measures are allowed. Palliative limited radiation therapy for pain reduction is allowed
Auricular Acupuncture in Patients With Multiple Myeloma

In the present study, the effect of ear acupressure treatment according to the NADA protocol on the quality of life of patients with multiple myeloma (all stages) will be investigated. Furthermore, the effect of ear acupressure on anxiety and depression, pain, fatigue and sleep of the patients will be assessed.


Eligibility Criteria:
Inclusion Criteria:

* Adult patients with multiple myeloma (all stages) on current therapy, who suffer from persistent disease- or therapy-associated symptoms and limitations (screening by distress thermometer, score ≥ 5)
* Informed consent.

Exclusion Criteria:

* medical reasons or
* a mental condition which, in the opinion of the investigator, does not allow the patient to participate in the study,
* a planned radiation therapy in the area of the skull (to avoid potential scattered radiation),
* a missing legally binding signature on the informed consent form,
* participation in another acupuncture/acupressure study.